IL-6
Pro-inflammatory cytokine — acute phase driver
- Expression
- Elevated
- Evidence level
- moderate
- Targeted by
- Tocilizumab
Role in pathogenesis
IL-6 is elevated in TRAPS and drives acute phase responses including CRP and SAA production. Tocilizumab (anti-IL-6R) has shown efficacy in case reports when IL-1 and TNF blockade failed, supporting a pathogenic role for IL-6.
Targeting drugs (1)
| Drug | Mechanism | Response | Line |
|---|---|---|---|
| Tocilizumab | Anti-IL-6 receptor monoclonal antibody | Case reports of efficacy | Alternative |